[02:16] A That'll be so nice
Cagrilintide and the combination drug CagriSema are investigational treatments currently undergoing regulatory review
Omeprazole is used to reduce stomach acid, but it may increase the risk of kidney-related problems
Glucagon-like peptide-1 receptor (GLP-1) agonists, widely used to treat obesity and diabetes, may also improve key outcomes for patients with Crohns disease, according to a large real-world study presented during the 2026 Crohns & Colitis Congress, a partnership of AGA and the Crohn's & Colitis Foundation, taking place in Las Vegas
Researchers studying simultaneous fat loss and muscle preservation will recognize this as addressing the most common complaint about GLP-1 therapy
Begin exploring Mind, Body, and Spirit below MBS Quiet the noise